BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34621742)

  • 1. Classification of Estrogen Receptor-Positive Breast Cancer Based on Immunogenomic Profiling and Validation at Single-Cell Resolution.
    Ma X; Chen H; Yang M; Ke Z; Wang M; Huang T; Li L
    Front Cell Dev Biol; 2021; 9():722841. PubMed ID: 34621742
    [No Abstract]   [Full Text] [Related]  

  • 2. Three Immune-Associated Subtypes of Diffuse Glioma Differ in Immune Infiltration, Immune Checkpoint Molecules, and Prognosis.
    Zhou Q; Yan X; Liu W; Yin W; Xu H; Cheng D; Jiang X; Ren C
    Front Oncol; 2020; 10():586019. PubMed ID: 33425739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune gene expression profiling reveals heterogeneity in luminal breast tumors.
    Zhu B; Tse LA; Wang D; Koka H; Zhang T; Abubakar M; Lee P; Wang F; Wu C; Tsang KH; Chan WC; Law SH; Li M; Li W; Wu S; Liu Z; Huang B; Zhang H; Tang E; Kan Z; Lee S; Park YH; Nam SJ; Wang M; Sun X; Jones K; Zhu B; Hutchinson A; Hicks B; Prokunina-Olsson L; Shi J; Garcia-Closas M; Chanock S; Yang XR
    Breast Cancer Res; 2019 Dec; 21(1):147. PubMed ID: 31856876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer.
    Cao J; Li J; Yang X; Li P; Yao Z; Han D; Ying L; Wang L; Tian J
    Cancer Med; 2021 Aug; 10(15):5375-5391. PubMed ID: 34165261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-Related Gene-Based Novel Subtypes to Establish a Model Predicting the Risk of Prostate Cancer.
    Zhang E; He J; Zhang H; Shan L; Wu H; Zhang M; Song Y
    Front Genet; 2020; 11():595657. PubMed ID: 33281882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a prognostic 15-gene signature for stratifying HER2+/ER+ breast cancer.
    Liu Q; Huang S; Desautels D; McManus KJ; Murphy L; Hu P
    Comput Struct Biotechnol J; 2023; 21():2940-2949. PubMed ID: 37216014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers.
    O'Meara T; Marczyk M; Qing T; Yaghoobi V; Blenman K; Cole K; Pelekanou V; Rimm DL; Pusztai L
    JCO Precis Oncol; 2020; 4():. PubMed ID: 32923897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single-sample mRNA molecular classification of bladder cancer predicting prognosis and response to immunotherapy.
    Jin K; He M; Chen B; Zhou X; Zhang C; Zhang Z; Hu D; Jiang Z; Wei Q; Qiu S; Yang L
    Transl Androl Urol; 2022 Jul; 11(7):943-958. PubMed ID: 35958899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune gene signature delineates a subclass of thyroid cancer with unfavorable clinical outcomes.
    Zhi J; Yi J; Tian M; Wang H; Kang N; Zheng X; Gao M
    Aging (Albany NY); 2020 Apr; 12(7):5733-5750. PubMed ID: 32240105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Analysis of Regulatory Factors and Immune-Associated Patterns to Decipher Common and
    Li Y; Dong W; Zhang P; Zhang T; Ma L; Qu M; Ma X; Zhou X; He Q
    Front Cell Dev Biol; 2021; 9():750897. PubMed ID: 34733851
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel immune subtypes identification of HER2-positive breast cancer based on immunogenomic landscape.
    Huang L; Liu X; Li L; Wang L; Wu N; Liu Z
    Med Oncol; 2022 May; 39(5):92. PubMed ID: 35568771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenomics model for personalized medicine in cervical cancer: Cross-talk of gene expressions and pathological images related to oxidative stress.
    Li J; Chen S; Wu J; Liu X; Liu H; Liu Y; Zhu Z
    Environ Toxicol; 2024 Feb; 39(2):751-767. PubMed ID: 37755325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
    Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
    Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Breast Cancer Subtypes by Integrating Genomic Analysis with the Immune Microenvironment.
    Ding R; Liu Q; Yu J; Wang Y; Gao H; Kan H; Yang Y
    ACS Omega; 2023 Apr; 8(13):12217-12231. PubMed ID: 37033796
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification of Epithelial-Mesenchymal Transition-Related lncRNA With Prognosis and Molecular Subtypes in Clear Cell Renal Cell Carcinoma.
    Zhong W; Zhang F; Huang C; Lin Y; Huang J
    Front Oncol; 2020; 10():591254. PubMed ID: 33324563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two immune-enhanced molecular subtypes differ in inflammation, checkpoint signaling and outcome of advanced head and neck squamous cell carcinoma.
    Cao B; Wang Q; Zhang H; Zhu G; Lang J
    Oncoimmunology; 2018; 7(2):e1392427. PubMed ID: 29308323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Breast Cancer Immune Subtypes by Analyzing Bulk Tumor and Single Cell Transcriptomes.
    Yao J; Li S; Wang X
    Front Cell Dev Biol; 2021; 9():781848. PubMed ID: 35047498
    [No Abstract]   [Full Text] [Related]  

  • 18. The molecular basis of breast cancer pathological phenotypes.
    Heng YJ; Lester SC; Tse GM; Factor RE; Allison KH; Collins LC; Chen YY; Jensen KC; Johnson NB; Jeong JC; Punjabi R; Shin SJ; Singh K; Krings G; Eberhard DA; Tan PH; Korski K; Waldman FM; Gutman DA; Sanders M; Reis-Filho JS; Flanagan SR; Gendoo DM; Chen GM; Haibe-Kains B; Ciriello G; Hoadley KA; Perou CM; Beck AH
    J Pathol; 2017 Feb; 241(3):375-391. PubMed ID: 27861902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-Omics Characterization of Tumor Microenvironment Heterogeneity and Immunotherapy Resistance Through Cell States-Based Subtyping in Bladder Cancer.
    Hu R; Tao T; Yu L; Ding Q; Zhu G; Peng G; Zheng S; Yang L; Wu S
    Front Cell Dev Biol; 2021; 9():809588. PubMed ID: 35223867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics.
    Li CY; Xiong DD; Huang CQ; He RQ; Liang HW; Pan DH; Wang HL; Wang YW; Zhu HW; Chen G
    Med Sci Monit; 2017 Apr; 23():1857-1871. PubMed ID: 28416776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.